|Datasheet||Specific References||Reviews||Related Products||Protocols|
|ORF Clone of Rattus norvegicus surfactant protein D DNA.|
|SPD, SP-D, Sftpd|
|Identical with the Gene Bank Ref. ID sequence except for the point mutation 723 G/A not causing the amino acid variation.|
|Whatman FTA elute card (Cat: WB120410) contains 5-10 μg of plasmid.|
|The Whatman FTA elute card can be stored at room temperature for three months under dry condition.|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Rat SFTPD Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||RG80256-G-F|
|Rat SFTPD Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||RG80256-G-H|
|Rat SFTPD Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||RG80256-G-M|
|Rat SFTPD Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||RG80256-G-N|
|Rat SFTPD Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||RG80256-G-Y|
|Product name||Product name|
Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia, asthma, and bleomycin injury. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides it is involved in the development of acute and chronic inflammation of the lung. Several human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.